Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status

Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients with a poor performance status. If the medication cannot be taken...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanai, Osamu, Kim, Young Hak, Nakatani, Koichi, Fujita, Kohei, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458002/
https://www.ncbi.nlm.nih.gov/pubmed/28588841
http://dx.doi.org/10.1002/ccr3.973
_version_ 1783241660521512960
author Kanai, Osamu
Kim, Young Hak
Nakatani, Koichi
Fujita, Kohei
Mio, Tadashi
author_facet Kanai, Osamu
Kim, Young Hak
Nakatani, Koichi
Fujita, Kohei
Mio, Tadashi
author_sort Kanai, Osamu
collection PubMed
description Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients with a poor performance status. If the medication cannot be taken by mouth, the patient may be given alectinib through a nasogastric tube.
format Online
Article
Text
id pubmed-5458002
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54580022017-06-06 Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status Kanai, Osamu Kim, Young Hak Nakatani, Koichi Fujita, Kohei Mio, Tadashi Clin Case Rep Case Reports Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients with a poor performance status. If the medication cannot be taken by mouth, the patient may be given alectinib through a nasogastric tube. John Wiley and Sons Inc. 2017-04-26 /pmc/articles/PMC5458002/ /pubmed/28588841 http://dx.doi.org/10.1002/ccr3.973 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Kanai, Osamu
Kim, Young Hak
Nakatani, Koichi
Fujita, Kohei
Mio, Tadashi
Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
title Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
title_full Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
title_fullStr Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
title_full_unstemmed Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
title_short Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
title_sort nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458002/
https://www.ncbi.nlm.nih.gov/pubmed/28588841
http://dx.doi.org/10.1002/ccr3.973
work_keys_str_mv AT kanaiosamu nasogastrictubeadministeredalectinibachievedlongtermsurvivalinacrizotinibrefractorynonsmallcelllungcancerpatientwithapoorperformancestatus
AT kimyounghak nasogastrictubeadministeredalectinibachievedlongtermsurvivalinacrizotinibrefractorynonsmallcelllungcancerpatientwithapoorperformancestatus
AT nakatanikoichi nasogastrictubeadministeredalectinibachievedlongtermsurvivalinacrizotinibrefractorynonsmallcelllungcancerpatientwithapoorperformancestatus
AT fujitakohei nasogastrictubeadministeredalectinibachievedlongtermsurvivalinacrizotinibrefractorynonsmallcelllungcancerpatientwithapoorperformancestatus
AT miotadashi nasogastrictubeadministeredalectinibachievedlongtermsurvivalinacrizotinibrefractorynonsmallcelllungcancerpatientwithapoorperformancestatus

Ejemplares similares